Etid klinik pou Sipwa nan Arizona
29 etid pou Sipwa ap chèche patisipan nan sit nan Arizona.
Vil nan Arizona
Tèks ofisyèl etid la (Anglè)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Headlands Research - Scottsdale /ID# 282571, Scottsdale
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07752979Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, Tempe
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT07837973A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Care Access - 801 South Power Road, Mesa, Mesa
- Absolute Clinical Research, Phoenix
- Synexus Clinical Research US, Inc./Orange Grove Family Practice, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT07794579A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- University of Arizona, Tucson
Ap rekriteFaz 3
Laj 6 a 17 · Tout sèks · Mizajou Sep 24, 2026 · NCT06672549A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Tucson Clinical Research Institute, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07282600Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Synexus Clinical Research US, Inc., Phoenix
- Medical Advancement Centers of Arizona, Phoenix
Ap rekriteFaz 3
Laj 45 a 99 · Tout sèks · Mizajou Sep 22, 2026 · NCT07037433Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Care Access - 801 South Power Road, Mesa, Mesa
- Elite Pain and Spine Institute - South Crimson Road, Mesa
- Elite Clinical Studies, LLC, Phoenix
- ak 1 plis
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07353931A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- Headlands Research - Scottsdale, Scottsdale
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07321886A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Mesa
- Research Site, Phoenix
- Research Site, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07784270A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
- Headlands Research - Scottsdale, Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589608A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- RIO Clinical Trials - Phoenix, Phoenix
- Headlands Research - Scottsdale, Scottsdale
- Novak Clinical Research - Tucson - North La Cholla Boulevard, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07392190A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Peoria
- AURORA-2 Clinical Site, Phoenix
- AURORA-2 Clinical Site, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743450A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Phoenix
- AURORA-1 Clinical Site, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07743463A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Arizona Clinical Trials, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Arizona Clinical Trials, Tucson
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT07351045A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Helios Clinical Research - Phoenix, Phoenix
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 14, 2026 · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Chandler
- ACCOMPLISH-2 Research Site, Phoenix
- ACCOMPLISH-2 Research Site, Sun City West
- ak 1 plis
Ap rekriteFaz 3Volontè an sante akeyi
Laj 18 a 79 · Tout sèks · Mizajou Sep 11, 2026 · NCT07654374AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Dignity Health, Mercy Gilbert, Gilbert
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07571109A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, Gilbert
- Synexus Clinical Research US, Inc., Phoenix
- Pima Heart, Tucson
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT07215559A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler
- Headlands Research - Scottsdale, Scottsdale
- The Institute for Liver Health II dba Arizona Liver Health-Tucson, Tucson
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 8, 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Medical Dermatology Specialists, Phoenix
Ap rekriteFaz 4
Laj 18 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Phoenix
- Kailera Clinical Site, Sun City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284901Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Sun City
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Gilbert Center for Family Medicine, Gilbert
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Sep 3, 2026 · NCT07684144Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Arizona Clinical Trials, Chandler
- Epic Medical Research - Sun City, Sun City
Ap rekriteFaz 3
Laj 18 a 99 · Tout sèks · Mizajou Aug 27, 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Mesa
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT07784725Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
- Exponent Phoenix, Phoenix
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07776678Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Phoenix
- ACCOMPLISH-1 Research Site, Sun City West
- ACCOMPLISH-1 Research Site, Tucson
Ap rekriteFaz 3
Laj 18 a 79 · Tout sèks · Mizajou Aug 10, 2026 · NCT07654361Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- The University of Arizona College of Medicine- Phoenix, Phoenix
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Nov 14, 2025 · NCT06499857Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.